BTK and Alzheimer disease: A phase 2, randomized, double-blind, placebo-controlled, multicenter proof-of-concept study on rilzabrutinib, a BTK inhibitor (Figure 3b), is currently recruiting 136 adult (18 years and older) patients with moderate-to-severe AD who are inadequate responders or intolerant to topical corticosteroids.